High-content screening of small molecule inhibitors from nature that target prostate cancer metabolism
This project will screen and evaluate a library of 472 novel compounds that were isolated from Australian plants, fungi and marine organisms. Compounds that inhibit metabolic pathways critical for prostate cancer growth and survival will be chosen. This project will identify new inhibitors from nature, providing knowledge for future large-scale screens and helping develop new anticancer agents.
Investigators
| Rohan Davis | Griffith Institute for Drug Discovery & APCRC-Q |
| Colleen Nelson | APCRC-Q, IHBI, QUT, TRI |
| Martin Sadowski | APCRC-Q, IHBI, QUT, TRI |
Administering Institution
Griffith University
Duration
2017 - 2018
Funding
| PCFA | $98 500 |
